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Abstract
Background: Central venous catheters (CVC) removal and reinsertion of a new CVC in the setting of central line
associated bloodstream infections (CLABSI) is not always possible in septic patients. The purpose of this study was
to evaluate the outcome of patients with Staphylococcus aureus-CLABSI (SA-CLABSI) who had their CVCs exchanged
over guidewire for minocycline/rifampin-coated (M/R)-CVC within seven days of bacteremia.
Methods: Each case was matched with two control patients who had SA-CLABSI and had their CVC removed
within seven days and two control patients who had their CVC retained beyond seven days. In addition, an in vitro
model was developed for exchange of catheters.
Results: We identified 40 patients with SA-CLABSI. Eight patients had their CVC exchanged over guidewire with
M/R-CVC and were compared to 16 patients who had their CVC removed and 16 other patients who had their CVC
retained. Patients who had their CVC exchanged over guidewire had a similar clinical response and relapse rates
compared to patients whose CVC was removed or retained. However the rate of overall mortality was higher in
patients who retained their CVC compared to those whose CVC was exchanged or removed (p = 0.034). The in vitro
catheter exchange model showed that catheter exchange over guidewire using M/R-CVC completely prevented
biofilm colonization compared to exchange using uncoated CVC (p < 0.0001).
Conclusions: In the setting of SA-CLABSI, exchanging the CVC over guidewire with M/R-CVC could be an
alternative to removing the CVC and reinserting another CVC at a different site and may be associated with a lower
rate of overall mortality. Further large prospective randomized clinical trials are warranted.
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Background
Central line associated bloodstream infections (CLABSI)
are a serious complication of central venous catheters
(CVCs). Staphylococcus aureus is the second most
common pathogen causing bacteremia and is associated
with high morbidity and mortality in critically ill pa-
tients. Removal of the CVC is not always feasible
in the setting of coagulopathy, thrombocytopenia and
neutropenia. The latest Infectious Diseases Society of
America (IDSA) guidelines for the treatment of CLABSI
advise for exchanging the catheter for S. aureus
bacteremia with a B-III level of recommendation [1].
We have previously demonstrated that exchanging
CVC over guidewire for minocycline-rifampin coated
CVC (M/R-CVC) improves the outcome of CLABSI for
different pathogens [2].
In this study, we are presenting in-vivo and in-vitro
data about the exchange of CVC for M/R-CVCs in the
setting of S. aureus CLABSI.
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This is a retrospective chart review of all the patients with
S. aureus CLABSI identified at The University of Texas
MD Anderson Cancer Center who had their CVC
exchanged over guidewire for M/R-CVC within seven
days of S. aureus bacteremia between January 2005 and
December 2011. This retrospective study was approved by
the MD Anderson Cancer Center Institutional Review
Board, and a waiver of informed consent was obtained
to access patients’ electronic medical records. In this
matched retrospective cohort study, each case was
matched with two control patients who had S. aureus
CLABSI and had their CVC removed within seven
days and two other control patients who had their
CVC retained beyond seven days. Control patients were
matched based on cancer type (hematological versus solid
malignancy), neutropenia status and organism susceptibil-
ity. Data were collected from the institutional electronic
medical records and included demographic information,
clinical characteristics, laboratory data, therapy, as well as
outcome. Patients were followed for 3 months from the
date of bacteremia.
In vitro exchange model experiment
In vitro exchange model was developed in our lab. Un-
coated CVCs were placed in a tall glass tube (2cm×20cm)
containing 75 ml of bovine calf serum for 24 h for precon-
ditioning. After 24 h, catheters were transferred into
Mueller-Hinton broth (MHB) inoculated with 1×105 of
MRSA, and allowed to form biofilm at 37°C for 24 h. The
MRSA isolate was susceptible to minocycline and rifam-
pin. After biofilm colonization, guidewires were inserted
into the lumen of the uncoated biofilm colonized-CVCs
and then the catheters were exchanged over the guide-
wires for fresh uncoated, M/R-, Chlorhexidine/Silver
Sulfadiazine (CHX/SS)-CVCs placed in a glass tube con-
taining 50% MHB and 50% bovine calf serum for 24 h. Six
segments were cut after incubation of exchanged CVCs
and sonicated in saline for 15 min. After sonication, each
sample was serially diluted and spread on to Trypticase
soy agar + 5% sheep blood for colony counting. The ex-
periments were repeated three times.
Statistical analysis
This was a multiple-group comparison study. The
chi-square or Fisher’s exact tests were used to compare
categorical variables, as appropriate. If a significant re-
sult (p ≤ .05) was detected, pairwise comparisons bet-
ween individual groups were performed to identify the
significant differences. The Kruskal-Wallis test was used
to compare continuous variables. If a significant result
was detected, Wilcoxon rank sum tests were used for
the pair-wise comparisons. The α levels of the post-hoc
pairwise comparisons were adjusted using a sequential
Bonferroni adjustment to control type I error. All tests
except those for the pairwise comparisons were two-sided
at a significance level of 0.05. The statistical analyses
were performed using SAS version 9.3 (SAS Institute Inc.,
Cary, NC).
Definitions
CLABSI was defined per the Centers for Disease Control
and Prevention criteria [3]. Attributable mortality was
defined as clinical or microbiological evidence of infec-
tion at the time of death.
Relapse is a new episode of S. aureus bacteremia oc-
curring within the follow up period with an identical
antibiogram to the first isolate.
Results
The demographics and clinical characteristics of patients
are outlined in Table 1.
In the setting of S. aureus CLABSI, exchange over
guidewire with M/R-CVCs tended to have equivalent
outcomes in terms of defervescence within three days
and relapse when compared to situation where CVC
was removed or retained (p = 0.49 and 0.4 respectively)
(Table 1).
Overall mortality in the catheter exchange over guide-
wire group was similar compared to the catheter removal
group and statistically better compared to the catheter re-
tention group (p = 0.034).
An in-vitro model of catheter exchange showed that
M/R-CVC completely prevented biofilm colonization
after exchange of a highly colonized CVC which was
significantly better than exchange using uncoated CVC
(P < 0.0001) or CHX/SS-CVCs (P = 0.001) (Figure 1).
Discussion
S. aureus remains a leading cause of CLABSI in critically
ill patients associated with serious complications and
high mortality [4]. Clinical Practice Guidelines for the
Diagnosis and Management of Intravascular Catheter-
Related Infection caused by S. aureus continue to re-
commend early removal of the catheter and reinsertion
of the new catheter at a different vascular site [1]. Failure
to remove the catheter increases the risk of deep seated
complications related to S. aureus [1].
However, in the seriously ill patients with bacteremia
removal of culprit colonized CVC and reinsertion of
another CVC in a different vascular site may not always
be possible or achievable. Moreover, septic patients (par-
ticularly cancer and critically ill patients) either have no
other vascular access or the reinsertion of a new CVC at
the different site may be associated with mechanical
complications such as hemopneumothorax particularly
in the setting of disseminated intravascular coagulopathy
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(DIC) or concurrent thrombocytopenia [2]. Hence, the
risk of removing the CVC and reinserting a new one
might exceed the benefit of catheter removal.
The exchange of the culprit colonized CVC in the
setting of CLABSI for a new uncoated CVC has been
discouraged because of studies that showed transfer of
organisms from the lumen of the culprit CVC to the
new uncoated catheter during the exchange process
[5,6]. Our in vitro studies support this finding as they
suggest that if the newly exchanged CVC is uncoated
there is the risk of cross contamination (Figure 1) that
would lead to the perpetuation of the infection through
the newly colonized exchanged and uncoated CVC.
However, in vitro and in vivo studies have shown that
impregnating the internal and external surfaces of CVCs
with antibiotics (M/R) prevents the surface adherence
of the bacteria particularly S. aureus [7,8]. These anti-
biotic coated CVCs were also highly effective in pre-
venting CLABSI in high-risk patients [9,10].
In vitro data from this current study substantiate the
finding that these antibiotic impregnated catheters could
be used, not only for the prevention of infection, but also
for the management of infection during exchange. Our
in vitro exchange model showed that M/R-CVC com-
pletely prevent the intraluminal transfer of MRSA through
the guidewire during the exchange process whereas the
transfer of organisms occurs when an uncoated CVC or
CHX/SS-CVCs is used. The superiority of the M/R-CVC
over the second generation CHX/SS is consistent with
the previous findings in a large clinical trial whereby the
M/R-CVC was shown to be clinically superior to the first
generation CHX/SS [10].
Table 1 Clinical characteristics and outcomes
Characteristics and
outcomes
CVC retained for more
than 7 days since
bacteremia (n = 16)
Removed within
7 days of bacteremia
(n = 16)
Exchanged with antibiotic-coated
catheters within 7 days of
bacteremia (n = 8)
p-value
N (%) N (%) N (%)
Median age (years), (range) 52 (12–74) 62 (4–83) 55 (29–67) 0.24
Gender, male 10 (62.5%) 8 (50.0%) 2 (25.0%) 0.28
Type of cancer > .99
Hematologic malignancy 6 (37.5%) 6 (37.5%) 3 (37.5%)
Solid tumor 10 (62.5%) 10 (62.5%) 5 (62.5%)
Body temperature 0.41
≤ 36°C 2 (12.5%) 0 (0%) 1 (12.5%)
36°C −38°C 6 (37.5%) 5 (31.3%) 1 (12.5%)
≥ 38°C 8 (50.0%) 11 (68.7%) 6 (75.0%)
MIC of vancomycin 0.77
< 2.0 9 (56.2%) 9 (56.2%) 3 (37.5%)




Single 7 (43.8%) 6 (37.5%) 1 (12.5%)
Double 8 (50.0%) 9 (56.3%) 6 (75.0%)
Triple 1 (6.3%) 1 (6.3%) 1 (12.5%)
CVC location 0.22
Subclavian 7 (43.8%) 6 (37.5%) 6 (75.0%)
Jugular 2 (12.5%) 0 0
Basilic 7 (43.8%) 10 (62.5%) 2 (25.0%)
Defervescence within 3 days
of starting antibiotics
11 (68.8%) 14 (87.5%) 6 (75.0%) 0.49
Relapse within 3 months 2 (12.5%) 0 (0%) 1 (12.5%) 0.4
Death within 3 months 8 (50.0%) 4 (25.0%) 0 (0%) 0.034 CVC retained vs CVC
exchange: p = 0.02
Infection-related death within
3 months
5 (31.3%) 1 (6.3%) 0 (0%) 0.1
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We have recently showed that this novel approach of
exchanging colonized CVC in the setting of CLABSI
with a new M/R-CVC is highly useful in improving over-
all response rate and decreasing the risk of mechanic
failure as well as disease reoccurrence [2]. However, the
Chaftari et al. study had no comparative cohort in which
the CVC was retained as in this current study and there
was no microbiologically plausible in vitro model that
supported the clinical findings.
Our clinical data show that exchange over guidewire
with M/R-CVCs tended to have equivalent outcome to
catheter removal in terms of response to antimicrobial
therapy, relapse, mortality and infection related mor-
tality. Concurrently, exchange over guidewire using anti-
biotic coated catheters as well as CVC removal showed
an improved outcome in terms of mortality and possibly
infection related mortality when compared to retaining
the catheter (p = 0.034 and 0.1 respectively).
The clinical and in vitro data outlined above clearly
highlight the safety and efficacy of exchanging a CVC over
guidewire using M/R-CVCs in the setting of S. aureus
CLABSI. This approach is particularly useful in the septic
patients or the seriously ill cancer patients with either
thrombocytopenia or DIC and concurrent S. aureus
CLABSI whereby the likelihood of mechanical compli-
cations (such as hemorrhage) would be decreased by
avoiding the reinsertion of another CVC in a different
vascular site. In addition, the estimated comparative cost
savings at our institution (the exchange vs. reinsertion
procedure) is around $2250 for S. aureus CLABSI which
has major economic implications related to the manage-
ment of S. aureus CLABSI.
The current study is subject to several limitations. The
first is the small number of patients who had undergone
CVC exchange. This is due to the fact that the clinical
practice guidelines recommend CVC removal for the
management of S. aureus CLABSI. Another limitation is
the observational, retrospective, nonrandomized design,
although this was a matched cohort study. Patients were
not on defined prospective clinical protocols, and cli-
nical symptoms and signs were not consistently moni-
tored. Serial blood cultures were not always available
and bacteremia resolution was not always documented.
Conclusions
In the setting of S. aureus CLABSI, exchanging the CVC
guidewire with M/R-CVCs may be associated with a simi-
lar clinical response and relapse compared to catheter re-
moval. However, overall mortality was lower in patients
who had their CVC exchanged over a guidewire with an
M/R-CVC compared to those who retained their CVC. In
selected patients, this approach may serve as a safer and
more cost-effective alternative to CVC removal and re-
insertion of the central catheter in a different vascular site.
To validate our findings, further large prospective ran-
domized clinical trials are warranted.
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